Classified in: Health
Subjects: MAV, CFG

Media Advisory - Prime Minister's itinerary for Friday, May 24, 2024

OTTAWA, ON, May 23, 2024 /CNW/ -

Note: All times local

Greater Halifax Area, Nova Scotia

2:00 p.m.	The Prime Minister will make a health care announcement. A media availability will follow.

	Notes for media:
	Open coverage Media are asked to arrive no later than 1:15 p.m. Media interested in participating can contact [email protected] for details.

This document is also available at https://pm.gc.ca

SOURCE Prime Minister's Office

These press releases may also interest you

at 13:38	More than 2400 Canadians took to the streets of Toronto to raise an unprecedented $1.63 million for life-saving cancer research and clinical care at The Princess Margaret
	Thousands of participants raised $1.63 million at the 11th annual Journey to Conquer Cancer ? a new record for this event, presented by Starlight Investments benefiting the Princess Margaret Cancer Centre on June 16, 2024. This inclusive family and...
at 08:00	/R E P E A T -- MEDIA ADVISORY - Minister Hajdu to make major announcement for Northern Ontario/
	Please be advised that the Honourable Patty Hajdu, Minister of Indigenous Services, will make a funding announcement for the Weeneebayko Area Health Authority. Date: Monday, June 17, 2024Time: 12:00 p.m. (ET) Where:House of Commons Foyer (West...
at 07:45	Crisis Prevention Institute Launches New Neuroscience-based Training for Educators
	Today, Crisis Prevention Institute (CPI) announced the launch of Reframing Behavior ? its new groundbreaking, subscription-based, schoolwide training program that unpacks the latest neuroscience to help all educators build a more positive, supportive...
at 07:05	CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
	Positive results from the ECHO Phase III trial showed AstraZeneca's CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival...
at 03:50	Electra Therapeutics Presents Late-Breaking Clinical Data at EHA2024 from Ongoing Phase 1b Study of ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
	Electra Therapeutics, Inc., a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, announced the presentation of clinical data for ELA026 in secondary hemophagocytic...
15 jun 2024	Biotech entrepreneur donates $50 million to UC Irvine School of Biological Sciences
	The University of California, Irvine has received a $50 million donation from Orange County biotech entrepreneur Charlie Dunlop for the School of Biological Sciences. His gift will create an endowed fund that will provide unrestricted support for...
	More news about Health...

News published on 23 may 2024 at 18:17 and distributed by: